Bio-Rad Laboratories Peer Comparison
$364.15
$0.00 (0.00%)As on 15-Oct-2026 09:46EDT
Market cap
$9,762 Mln
Revenue (TTM)
$2,589 Mln
P/E Ratio
46.3
P/B Ratio
1.4
Div. Yield
0 %
Edit
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
9,762 | 12,507 | 10,508 | 11,040 | 10,599 |
Revenue ($ Mln) |
2,589 | 1,505 | 617 | 785 | 6,561 |
Net Profit ($ Mln) |
222.40 | 160.59 | -75.13 | 41.54 | -578.00 |
Net Margin (%) |
8.59 | 10.67 | -12.18 | 5.29 | -8.81 |
RoE (%) |
3.04 | 10.86 | -9.26 | 1.97 | -10.33 |
Price to Earnings |
46.27 | 78.01 | -- | 238.19 | -- |
Price-To-Book |
1.36 | 8.22 | 11.93 | 4.93 | 1.77 |
Income Statement ($ Mln)
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,589.30 | 1,504.87 | 616.91 | 785.10 | 6,561.10 |
|
Cost of Revenue
|
1,245.50 | 483.98 | 184.88 | 384.30 | 4,473.00 |
|
Gross Profit
|
1,343.60 | 942.44 | 443.88 | 347.62 | 2,139.40 |
|
Operating Expenses
|
1,108.90 | 833.56 | 520.41 | 335.50 | 2,373.70 |
|
Operating Profit (EBIT)
|
235.00 | 187.34 | -88.38 | 65.30 | -285.60 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
350.40 | 203.83 | -74.89 | 52.15 | -472.00 |
|
Provision for Tax
|
128.00 | 43.24 | 0.24 | 10.61 | 106.00 |
|
Profit after Tax (Net Income)
|
222.40 | 160.59 | -75.13 | 41.54 | -578.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 93.19 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
7,173.90 | 1,530.77 | 825.55 | 2,112.03 | 5,630.20 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
2,116.80 | 210.18 | 86.01 | 705.49 | 4,583.70 |
|
Current Liabilities
|
961.30 | 233.78 | 118.51 | 132.66 | 1,382.00 |
|
Total Liabilities
|
10,576.50 | 1,826.52 | 1,041.37 | 2,949.70 | 11,794.70 |
Assets ($ Mln)
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
7,231.50 | 630.60 | 355.40 | 1,749.63 | 9,133.70 |
|
Current Assets
|
3,020.50 | 1,344.12 | 674.67 | 1,200.55 | 2,462.20 |
|
Total Assets
|
10,576.50 | 1,826.52 | 1,041.37 | 2,949.70 | 11,794.70 |
|
Total Debt*
|
1,203.70 | 212.71 | 78.80 | 690.94 | 3,697.80 |
|
Net Current Assets
|
2,059.20 | 1,110.35 | 556.16 | 1,067.90 | 1,080.20 |
Cashflow ($ Mln)
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
532.20 | 238.66 | 136.05 | 117.42 | 623.80 |
|
Cash Flow from Investing Activities
|
-189.70 | -404.59 | -13.44 | -298.47 | -130.50 |
|
Cash from Financing Activities
|
-283.20 | 26.53 | 6.80 | -15.21 | -409.40 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
8.98 | 11.76 | -4.99 | 1.79 | -5.43 |
|
ROE (%)
|
3.04 | 10.86 | -9.26 | 1.97 | -10.33 |
|
ROA (%)
|
2.02 | 7.95 | -6.71 | 1.36 | -4.08 |
|
EBIT Margin (%)
|
15.42 | 13.63 | -1.34 | 9.87 | -4.47 |
|
Net Margin (%)
|
8.59 | 10.67 | -12.18 | 5.29 | -8.81 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
1.37 | 17.55 | -4.28 | 16.49 | -1.57 |
|
EBIT Growth (%)
|
-20.02 | 17.49 | 89.59 | 920.91 | -129.16 |
|
Net Profit Growth (%)
|
-30.32 | 8.72 | 11.20 | 400.42 | -184.08 |
|
EPS Growth (%)
|
-29.66 | 8.12 | 16.01 | 394.30 | -184.11 |
|
Book Value Growth (%)
|
2.19 | 17.33 | 2.26 | 2.16 | -9.82 |
Valuation Ratios
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 68.93 | -47.60 | 189.42 | -14.68 |
|
Price / Book Value
|
-- | 8.58 | 2.60 | 4.40 | 1.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | 53.25 | 436.68 | 50.32 | 81.94 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.11 | 0.00 | 0.00 | 0.26 | 0.65 |
|
Short term debt to equity ratio
|
0.06 | 0.01 | 0.01 | 0.01 | 0.01 |
|
Current Ratio
|
3.14 | 5.75 | 5.69 | 9.05 | 1.78 |
|
Quick Ratio
|
2.33 | 3.86 | 5.25 | 7.64 | 1.18 |
|
Interest Coverage
|
8.18 | 157.91 | -24,962.33 | 1.92 | -1.64 |
Operating Efficiency Ratios
| Bio-Rad Laboratories | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.06 | 12.65 | 8.21 | 20.09 | 17.36 |
|
Asset Turnover
|
0.24 | 0.74 | 0.55 | 0.26 | 0.46 |
|
Receivable days
|
65.39 | 46.54 | 48.40 | 72.41 | 58.79 |
|
Inventory Days
|
221.09 | 331.92 | 128.01 | 146.53 | 64.13 |
|
Payable days
|
37.02 | 26.16 | 23.54 | 29.05 | 58.13 |
|
Cash Conversion Cycle
|
249.46 | 352.30 | 152.87 | 189.88 | 64.79 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
